Search Results
Nov 05, 2025, 08:15 ET Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
placebo-controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with one or more weight-related comorbidities.5 People with diabetes were excluded.5
More news about: NOVO NORDISK INC.
Nov 05, 2025, 08:15 ET Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors
placebo-controlled trial evaluating the efficacy and safety of once-daily oral semaglutide 25 mg versus placebo in 307 adults with obesity (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) with one or more weight-related comorbidities.5 People with diabetes were excluded.5
More news about: NOVO NORDISK INC.
Nov 04, 2025, 16:01 ET MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
tolerability, PK, and pharmacodynamics (PD) of single and multiple ascending doses of DA-1726 in obese but otherwise healthy adults with a body mass index (BMI) of 30–45 kg/m². Each of the 4 cohorts presented in the poster included nine participants randomized 6:3 to receive four once-weekly subcutaneous doses
More news about: MetaVia Inc.
Nov 04, 2025, 12:04 ET Currax Announces ObesityWeek® Data Showing that CONTRAVE® Helps Curb Cravings and Offers Marked Effectiveness in Certain Populations with Obesity
reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure,
More news about: Currax Pharmaceuticals LLC
Nov 04, 2025, 12:00 ET RO TO PRESENT EIGHT RESEARCH ABSTRACTS AT OBESITYWEEK 2025
Patients with class IV obesity (BMI>50 kg/m²) face substantial health risks, but in-person care may be less desirable to these patients due to physical limitations and weight bias. This study examined the demographic and clinical characteristics of patients with BMI > 50 kg/m² seeking treatment
More news about: Ro
Nov 04, 2025, 10:30 ET Bariatric Beds Market to Reach $583.8 million, Globally, by 2034 at 5.3% CAGR: Allied Market Research
largely driven by the increasing global prevalence of obesity and obesity-related health conditions. As more individuals qualify as morbidly obese (with a BMI ≥ 40), healthcare providers are investing in specialized equipment that ensures safety, comfort, and effective treatment for this patient's population.
More news about: Allied Market Research
Nov 04, 2025, 08:00 ET Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek®
In this Phase 2 trial, men with BMI ≥27 kg/m2 with metabolic dysfunction associated steatohepatitis were randomized (1:1:1) to one of three treatments:1) LPCN 2401, 2) LPCN 2401
More news about: Lipocine Inc.
Nov 03, 2025, 03:47 ET 諾和諾德於香港推出體重管理藥物維秀美® （Wegovy®）
體重指數 BMI ≥ 30 kg/m²的成人，或 體重指數BMI ≥27 至 <30 kg/m²的成人並伴隨至少一項體重相關疾病，如高血糖（糖尿病前期或二型糖尿病）、高血壓、血脂異常、阻塞性睡眠窒息、心血管疾病等，或 12歲及以上患有肥胖症的青少年（體重指數 BMI ≥ 95百分位，依據美國疾病管制與預防中心所制定的性別與年齡特定體重指數圖表），且體重超過
More news about: 諾和諾德
Oct 30, 2025, 12:41 ET Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®
reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure,
More news about: Currax Pharmaceuticals LLC
Oct 29, 2025, 12:43 ET Currax Pharmaceuticals to Spotlight New Research at ObesityWeek® 2025 Highlighting Craving Control, Behavioral Adherence, and Subpopulation Outcomes with CONTRAVE®
reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure,
More news about: Currax Pharmaceuticals LLC
Oct 26, 2025, 20:00 ET Innovent's Mazdutide Shows Superiority in Glycemic Control with Weight Loss over Semaglutide in a Head-to-head Phase 3 Clinical Trial DREAMS-3
activity for chronic weight management in adult patients with an initial Body Mass Index (BMI) of: BMI ≥ 28 kg/m² (obesity); or BMI ≥ 24 kg/m² (overweight) in the presence of at least one weight-related comorbid condition
More news about: Innovent Biologics
Oct 23, 2025, 09:02 ET Currax Pharmaceuticals LLC to Provide CONTRAVE® at No Cost to Federal Employees During Government Shutdown
CONTRAVE?CONTRAVE is a prescription weight-loss medicine that may help some adults with a body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure,
More news about: Currax Pharmaceuticals LLC
Oct 23, 2025, 08:55 ET Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives
data, we identified high-responder subgroups that demonstrated particularly encouraging results. These subgroups, including participants with lower BMI and older demographics, showed the possibility of achieving over 1% reduction in HbA1c, a clinically meaningful outcome that potentially strengthens
More news about: Oramed Pharmaceuticals Inc.
Oct 22, 2025, 16:05 ET Viking Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
achieved following weekly subcutaneous dosing. This trial is a randomized, double-blind, placebo-controlled trial in approximately 180 adults with obesity (BMI ≥30 kg/m2). All participants will receive initial weekly subcutaneous doses of VK2735 or placebo for 19 weeks. Participants will subsequently transition
More news about: Viking Therapeutics, Inc.
Oct 22, 2025, 12:29 ET Surgeons: Obesity Isn't About Willpower -- It's a Treatable Medical Condition
U.S. Centers for Disease Control and Prevention defines obesity as having a body mass index (BMI) of 30 or higher, and severe obesity as a BMI of 40 or higher. Reframing Obesity as a Health Condition
More news about: American College of Surgeons
Oct 21, 2025, 16:01 ET Can Ozempic Slow Aging? New Study Raises Hope
system aging improved by approximately 4–5 years. Beyond Weight Loss: Analysis controlled for BMI, indicating benefits beyond semaglutide's known effect of visceral fat reduction. Predictive Insights:
More news about: TruDiagnostic
Oct 21, 2025, 11:00 ET RunStar® Expands Smart Scale Lineup With Three New Models Designed for Personalized Health Tracking
fat, including a breakdown of subcutaneous versus visceral fatMuscle mass, showing how much of the body's weight comes from muscleBMI, providing a general indicator of body composition based on height and weight
More news about: RunStar
Oct 21, 2025, 07:05 ET Viking Therapeutics Announces Initiation of VK2735 Maintenance Dosing Clinical Trial in Patients with Obesity
The VANQUISH-1 study is targeting enrollment of approximately 4,500 adults who do not have type 2 diabetes and who have obesity (BMI ≥30 kg/m2) or are overweight (BMI ≥27 kg/m2) with at least one weight-related co-morbid condition. The VANQUISH-2 study is targeting enrollment of approximately
More news about: Viking Therapeutics, Inc.
Oct 20, 2025, 14:31 ET Sōlaria Biō Announces New Bone Health Breakthrough with Bondia™
286 postmenopausal women and found that daily consumption of Bondia™ significantly slowed bone loss compared to placebo in women with osteopenia or a BMI greater than/equal to 30. "For decades, treatment options for bone loss have been limited, especially for women with early-stage
More news about: Sōlaria Biō
Oct 20, 2025, 09:00 ET SHEIN and Rap Superstar GloRilla Drop Fire-and-Ice-Inspired Collection Built for Self-Expression
her the title of Hottest Female Rapper of 2024. This year GloRilla became the youngest female artist to receive Songwriter of the Year at the BMI R&B/Hip-Hop Awards, further cementing her status as one of the premier artists of today.
More news about: SHEIN
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In
More news about: NOVO NORDISK INC.
Oct 20, 2025, 07:00 ET Novo Nordisk to present new data in oral semaglutide 25 mg (Wegovy® in a pill*) and obesity pipeline at ObesityWeek® 2025
indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In
More news about: NOVO NORDISK INC.
Oct 20, 2025, 07:00 ET CITY OF LONDON INVESTMENT GROUP PLC ("City of London" or "the Group" or "the Company" or "CLIG") TRADING UPDATE FOR THE QUARTER TO 30 SEPTEMBER 2025
presented as net of fee performance figures. The CLIM Global Emerging Markets strategy is shown against the S&P Emerging Frontier Super Composite BMI Net TR Index, the CLIM Global Developed CEF International Equity Strategy is shown against the MSCI ACWI ex-US Net TR Index, the CLIM Opportunistic Value
More news about: City of London Investment Group PLC
Oct 19, 2025, 20:10 ET 歌禮完成小分子GLP-1R激動劑ASC30治療肥胖症的每月一次皮下儲庫型治療制劑的美國IIa期研究受試者入組
ASC30每月一次皮下儲庫型治療制劑的IIa期研究是一項在美國開展的、為期 12 周、隨機、雙盲、安慰劑對照及多中心的臨床研究，旨在評估其在肥胖受試者（體重指數（BMI）≥ 30 kg/m2）或伴有至少一種體重相關合併症的超重受試者（27 kg/m2 ≤ BMI < 30 kg/m2）中的安全性、耐受性和療效。該研究分為不同劑量的三個隊列，共計65名受試者。預計將於2026年第一季度獲得頂線數據。 Ib期研究（
More news about: 歌禮製藥有限公司
Oct 19, 2025, 20:10 ET Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity
multi-center study conducted in the U.S. to evaluate the safety, tolerability and efficacy in participants with obesity (body mass index (BMI) ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2 but < 30 kg/m2) with at least one weight-related comorbidity. The study consists of three cohorts
More news about: Ascletis Pharma Inc.